.The CGDAA is committed to helping patients and carriers know they’re not alone.
CGDAA kicked off the annual Primary Immune Deficiency Treatment Consortium (PIDTC) meeting in Cincinnati on April 17, 2023, by awarding $25,000 to the PIDTC and the University of California, San Francisco (UCSF) to further the advancement of knowledge and research of Chronic Granulomatous Disease (CGD).
The CGDAA partnered with Remember The Girls to create a guide for carriers of X-Linked CGD. In addition, the CGDAA with support from Orchard Therapeutics created a resource for discussing x-Linked CGD with your medical provider.
The CGDAA created a YouTube channel where we publish additional resources for providers and CGD community members.
Dr. Jennifer Leiding in collaboration with CGDAA, PIDTC, and Dr. Mary Ann Miranda developed a new study that allowed X-linked carriers of CGD to self-report their symptoms reveals a broader range of health problems associated with carrier status, requiring appropriate diagnosis and treatment, The study was the first of its kind at this scale for X-linked carriers with a total of 171 respondents. Learn more.
Copyright © 2018 Chronic Granulomatous Disease Association of America - All Rights Reserved. Sec501(c)3 tax-exempt non-profit organization
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The contents of the CGD Association of America site, such as text, graphics, images, and other material contained on the CGDAA Site (“Content”) are for informational purposes only. The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding CGD or any medical condition.